Lonza– tag –
-
Cell Therapy Consumables Market Set for $7.53 Billion Surge by 2032, Fueled by Automation and Closed Systems
Credence Research India Overview A new report from Credence Research projects the global cell therapy consumables market will reach $7.53 billion by 2032. This significant growth is primarily driven by the expanding adoption of advanced ... -
CDMOs Accelerate GLP-1 Manufacturing, Outpacing Traditional Facility Builds to Meet Soaring Demand
Pharma Advancement USA Overview Contract Development and Manufacturing Organizations (CDMOs) are rapidly scaling their manufacturing capabilities for GLP-1 receptor agonists, providing quicker solutions than ground-up facility constructi... -
July 2026 Pharma M&A Review Highlights Manufacturing Partnerships and AI Innovation as Key Trends, Featuring Major Investments by Lonza, AGC Biologics, and Evonik
Biospectrum Jobs India Overview A July 2026 review of pharmaceutical M&A activities identifies manufacturing partnerships and AI innovation as critical emerging trends. Key players like Lonza expanded biopharmaceutical alliances, AGC... -
Point-of-Care Cell Therapy Manufacturing Surges Forward with Miltenyi Biotec’s CliniMACS Prodigy and Octane Medical’s Cocoon Systems
BioPharm International USA Overview Miltenyi Biotec's CliniMACS Prodigy and Octane Medical Group's Cocoon systems are emerging as pivotal technologies for accelerating point-of-care (PoC) manufacturing in cell therapy. These modular, clo... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Leading CDMOs Lonza, Samsung Biologics, Charles River Laboratories Spearhead Viral Vector Production, Legend Biotech Drives CAR-T Commercialization
GENE ONLINE|News & Opinion. Blog USA Overview Lonza, Samsung Biologics, and Charles River Laboratories are leading the complex viral vector manufacturing essential for scaling cell and gene therapies (CGTs), while Legend Biotech is drivi... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ... -
Cell & Gene Therapy Manufacturing Faces Deepening Bottlenecks: AmplifyBio, Exothera Close; Thermo Fisher Cuts Viral Vector Jobs, but FDA Eases Regulations to Support Growth
Endpoints News Global Overview Despite cell and gene therapies becoming a commercial reality, manufacturing remains the primary bottleneck. The CDMO sector is struggling with overcapacity and underfunding, leading to closures like Amplif... -
Fujifilm Prepares for Patent Cliff with Strategic CDMO Investments; Samsung Biologics Acquires PolyPeptide for $1.8B, Entering Peptide Market
Endpoints News Global Overview The pharmaceutical industry faces a 'patent cliff' with ~$300 billion in branded drug revenues at risk from 2025-2030, driving active deals for portfolio expansion and cost efficiency. Contract Development ... -
Repligen Acquires BioLife Solutions for ~$1.5B, Expanding Cell Therapy Services; Beone Medicines Invests $300M in US Manufacturing Expansion
Endpoints News USA Overview Repligen has announced the acquisition of cell processing service provider BioLife Solutions for approximately $1.5 billion, significantly broadening its capabilities within the cell therapy sector. Concurrent...
